1
|
Roser E, Harter P, Zocholl D, Denschlag D, Chekerov R, Wimberger P, Kurzeder C, Hasenburg A, Muallem MZ, Mustea A, Emons G, Zeimet AG, Beck F, Arndt T, Brucker SY, Kommoss S, Heitz F, Welz J, Egger EK, Kalder M, Buderath P, Klar M, Marth C, Ulrich UA, Weigel M, Traub L, Anthuber C, Strauss H, Hanker L, Link T, Kubiak K, Melekian B, Hornung D, Pölcher M, Lampe B, Krauß T, Keilholz U, Flörcken A, Pietzner K, Sehouli J. Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1). Int J Gynecol Cancer 2023; 33:223-230. [PMID: 36631151 DOI: 10.1136/ijgc-2022-003800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
OBJECTIVE Gynecological sarcomas account for 3% of all gynecological malignancies and are associated with a poor prognosis. Due to the rarity and heterogeneity of gynecological sarcomas there is still no consensus on optimal therapeutic strategies. This study's objective was to describe the treatment strategies used in patients with gynecological sarcomas in the primary course of disease. METHODS The German prospective registry for gynecological sarcoma (REGSA) is the largest registry for gynecological sarcomas in Germany, Austria and Switzerland. Primary inclusion criteria for REGSA are histological diagnosis of sarcoma of the female genital tract, sarcoma of the breast or uterine smooth muscle tumors of uncertain malignant potential (STUMP). We evaluated data of the REGSA registry on therapeutic strategies used for primary treatment from August 2015 to February 2021. RESULTS A total of 723 patients from 120 centers were included. Data on therapeutic strategies for primary treatment were available in 605 cases. Overall, 580 (95.9%) patients underwent primary surgery, 472 (81.4%) of whom underwent only hysterectomy. Morcellation was reported in 11.4% (n=54) of all hysterectomies. A total of 42.8% (n=202) had no further surgical interventions, whereas an additional salpingo-ophorectomy was performed in 54% (n=255) of patients. An additional lymphadenectomy was performed in 12.7% (n=60), an omentectomy in 9.5% (n=45) and intestinal resection in 6.1% (n=29) of all patients. Among 448 patients with available information, 21.4% (n=96) received chemo- or targeted therapies, more commonly as single-agent treatment than as drug combinations. Information about anti-hormonal treatment was available for 423 patients, among which 42 (9.9%) received anti-hormonal treatment, 23 (54.8%) of whom with low-grade endometrial stroma sarcomas. For radiotherapy, data of 437 patients were available, among which 29 (6.6%) patients underwent radiotherapy. CONCLUSION Our study showed that treatment of patients with gynecologic sarcomas is heterogeneous. Further trials are needed along with more information on treatment modalities, therapy response and patient-reported outcomes to implement new treatment strategies.
Collapse
Affiliation(s)
- Eva Roser
- Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Medical University, Berlin, Germany
| | - Philipp Harter
- Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany
| | - Dario Zocholl
- Institute of Biometry and Clinical Epidemiology, Charité-Universitaetsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Dominik Denschlag
- Department of Gynecology, Hochtaunus-Kliniken gGmbH, Bad Homburg, Germany
| | - Radoslav Chekerov
- Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Medical University, Berlin, Germany
| | - Pauline Wimberger
- Department of Obstetrics and Gynecology, University of Dresden, TU Dresden, Dresden Germany and National Center for Tumor Diseases (NCT/UCC), Dresden, Germany
| | - Christian Kurzeder
- Department of Obstetrics and Gynecology, Universitätsspital Basel, Basel, Switzerland
| | | | - Mustafa-Zelal Muallem
- Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Medical University, Berlin, Germany
| | - Alexander Mustea
- Department of Gynecology and Gynecological Oncology, Bonn University Hospital, Bonn, Germany
| | - Guenter Emons
- Department of Gynecology and Obstetrics, University Medicine Goettingen, Goettingen, Germany
| | - A G Zeimet
- Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Innsbruck, Austria
| | - Felix Beck
- Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Medical University, Berlin, Germany
| | - Tjadina Arndt
- Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Medical University, Berlin, Germany
| | - Sara Y Brucker
- Department of Women's Health, Tübingen University Hospital, Tuebingen, Germany
| | - Stefan Kommoss
- Department of Women's Health, Tübingen University Hospital, Tuebingen, Germany
| | - Florian Heitz
- Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany
| | - Julia Welz
- Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany
| | - Eva-Katharina Egger
- Department of Gynecology and Gynecological Oncology, Bonn University Hospital, Bonn, Germany
| | - Matthias Kalder
- Department of Gynecology and Obstetrics, University Clinic Gießen and Marburg, Marburg, Germany
| | - Paul Buderath
- Department of Gynecology and Obstetrics, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
| | - Maximilian Klar
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg, Germany
| | - Christian Marth
- Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Innsbruck, Austria
| | - Uwe Andreas Ulrich
- Department of Obstetrics and Gynecology, Martin Luther Hospital Berlin, Berlin, Germany
| | - Michael Weigel
- Department of Obstetrics and Gynecology, Leopoldina Krankenhaus Schweinfurt, Schweinfurt, Germany
| | - Lea Traub
- Department of Obstetrics and Gynecology, Technische Universität Munich, Munich, Germany
| | - Christoph Anthuber
- Department of Obstetrics and Gynecology, Klinikum Starnberg, Starnberg, Germany
| | - Hans Strauss
- Department of Obstetrics and Gynecology, University of Halle (Saale), Halle, Germany
| | - Lars Hanker
- Department of Obstetrics and Gynecology, University of Schleswig-Holstein, Luebeck, Germany
| | - Theresa Link
- Department of Obstetrics and Gynecology, University of Dresden, TU Dresden, Dresden Germany and National Center for Tumor Diseases (NCT/UCC), Dresden, Germany
| | - Karol Kubiak
- Department of Obstetrics and Gynecology, St. Franziskus Hospital Münster, Muenster, Germany
| | - Badrig Melekian
- Department of Obstetrics and Gynecology, Marienkliniken Siegen, Siegen, Germany
| | - Daniela Hornung
- Department of Obstetrics and Gynecology, Vidiakliniken, Standort Diakonissenkrankenhaus, Karlsruhe, Germany
| | - Martin Pölcher
- Department of Gynecologic Oncology, Rotkreuzklinikum Munich, Munich, Germany
| | - Bjoern Lampe
- Department of Obstetrics and Gynecology, Florence-Nightingale-Hospital, Kaiserswerther Diakonie, Duesseldorf, Germany
| | - Thomas Krauß
- Department of Obstetrics and Gynecology, Klinikum Passau, Passau, Germany
| | - Ulrich Keilholz
- Charité Comprehensive Cancer Center and German Cancer Consortium, Berlin, Germany
| | - Anne Flörcken
- Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Klaus Pietzner
- Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Medical University, Berlin, Germany
| | - Jalid Sehouli
- Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Medical University, Berlin, Germany .,Charité Comprehensive Cancer Center and German Cancer Consortium, Berlin, Germany
| |
Collapse
|
2
|
Leitner K, Tsibulak I, Wieser V, Penz M, Fiegl H, Marth C, Zeimet AG. JARID1B beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1746162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
3
|
Steinkasserer L, Zeimet AG, Marth C. Wirksamkeit der Ovarialkarzinom-Früherkennung: Eine Simulationsstudie basierend auf Daten aus dem Klinischen Tumorregister der AGO. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0039-3403399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Affiliation(s)
- L Steinkasserer
- Universitätsklinik für Frauenheilkunde der Medizinischen Universität Innsbruck
| | - A G Zeimet
- Universitätsklinik für Frauenheilkunde der Medizinischen Universität Innsbruck
| | - C Marth
- Universitätsklinik für Frauenheilkunde der Medizinischen Universität Innsbruck
| |
Collapse
|
4
|
Reiser E, Hagenbuchner J, Ausserlechner MJ, Kyvelidou C, Seeber B, Sopper S, Tsibulak I, Wieser V, Roessler J, Marth C, Zeimet AG, Fiegl H. Effekte von D,L-Methadon auf Tumor Sphäroide von Ovarialkarzinompatientinnen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0039-3403396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Affiliation(s)
- E Reiser
- Universitätsklinik für Gynäkologie und Geburtshilfe der Med. Universität Innsbruck
| | - J Hagenbuchner
- Department für Kinder- und Jugendheilkunde, Pädiatrie II der Med. Universität Innsbruck
| | - M J Ausserlechner
- Department für Kinder- und Jugendheilkunde, Pädiatrie II der Med. Universität Innsbruck
| | - C Kyvelidou
- Universitätsklinik für Gynäkologische Endokrinologie und Reproduktionsmedizin der Med. Universität Innsbruck
| | - B Seeber
- Universitätsklinik für Gynäkologische Endokrinologie und Reproduktionsmedizin der Med. Universität Innsbruck
| | - S Sopper
- Internal Medicine V, der Med. Universität Innsbruck
- Tiroler Krebsforschungsinstitut
| | - I Tsibulak
- Universitätsklinik für Gynäkologie und Geburtshilfe der Med. Universität Innsbruck
| | - V Wieser
- Universitätsklinik für Gynäkologie und Geburtshilfe der Med. Universität Innsbruck
| | - J Roessler
- Universitätsklinik für Gynäkologie und Geburtshilfe der Med. Universität Innsbruck
| | - C Marth
- Universitätsklinik für Gynäkologie und Geburtshilfe der Med. Universität Innsbruck
| | - A G Zeimet
- Universitätsklinik für Gynäkologie und Geburtshilfe der Med. Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Gynäkologie und Geburtshilfe der Med. Universität Innsbruck
| |
Collapse
|
5
|
Wieser V, Abdel Azim S, Kögl J, Knoll K, Tsibulak I, Marth C, Fiegl H, Zeimet AG. Tumornekrosefaktor definiert Outcome des Endometriumkarzinoms. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0039-3403404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Affiliation(s)
- V Wieser
- Universitätsklinik für Frauenheilkunde und Geburtshilfe Innsbruck, Medizinische Universität Innsbruck
| | - S Abdel Azim
- Universitätsklinik für Frauenheilkunde und Geburtshilfe Innsbruck, Medizinische Universität Innsbruck
| | - J Kögl
- Universitätsklinik für Frauenheilkunde und Geburtshilfe Innsbruck, Medizinische Universität Innsbruck
| | - K Knoll
- Universitätsklinik für Frauenheilkunde und Geburtshilfe Innsbruck, Medizinische Universität Innsbruck
| | - I Tsibulak
- Universitätsklinik für Frauenheilkunde und Geburtshilfe Innsbruck, Medizinische Universität Innsbruck
| | - C Marth
- Universitätsklinik für Frauenheilkunde und Geburtshilfe Innsbruck, Medizinische Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Frauenheilkunde und Geburtshilfe Innsbruck, Medizinische Universität Innsbruck
| | - A G Zeimet
- Universitätsklinik für Frauenheilkunde und Geburtshilfe Innsbruck, Medizinische Universität Innsbruck
| |
Collapse
|
6
|
Leitner K, Wieser V, Tsibulak I, Knoll K, Kögl J, Reimer D, Marth C, Fiegl H, Zeimet AG. Die Expression der Histon-Methyltransferase EZH2 beim Ovarialkarziom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0039-3403392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Affiliation(s)
- K Leitner
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - V Wieser
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - I Tsibulak
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - K Knoll
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - J Kögl
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - D Reimer
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - C Marth
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - A G Zeimet
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| |
Collapse
|
7
|
Kögl J, Wieser V, Knoll K, Leitner K, Tsibulak I, Fiegl H, Marth C, Zeimet AG. Hochregulation von PDL-1 Expression durch EGF und Zytokine in der Ovarialkarzinom-Zelllinie (HOC-7). Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0039-3403391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Affiliation(s)
- J Kögl
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - V Wieser
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - K Knoll
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - K Leitner
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - I Tsibulak
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - C Marth
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - A G Zeimet
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| |
Collapse
|
8
|
Oskay-Özcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J. Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol 2019; 29:910-916. [PMID: 29415128 DOI: 10.1093/annonc/mdy037] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Backround The primary aim of this study was to investigate information needs and treatment preferences of patients with ovarian cancer, focusing especially on physician-patient relationship and treatment. Patients and methods A questionnaire was developed based on the experiences of the national German survey 'Expression II', and was provided to patients with ovarian cancer either at initial diagnosis or with recurrent disease via Internet (online-version) or as print-out-version. Results From December 2009 to October 2012, a total of 1830 patients with ovarian cancer from eight European countries (Austria, Belgium, France, Germany, Italy, Poland, Romania, Spain) participated, 902 (49.3%) after initial diagnosis and 731 (39.9%) with recurrent ovarian cancer. The median age was 58 years (range 17-89). Nearly all patients (96.2%) had experienced upfront surgery followed by first-line chemotherapy (91.8%). The majority of patients were satisfied with the completeness and comprehensibility of the explanation about the diagnosis and treatment options. The three most important aspects, identified by patients to improve the treatment for ovarian cancer included: 'the therapy should not induce alopecia' (42%), 'there must be more done to counter fatigue' (34.5%) and 'the therapy should be more effective' (29.7%). Out of 659 (36%) patients, who were offered participation in a clinical trial, 476 (26%) were included. Conclusion This study underlines the high need of patients with ovarian cancer for all details concerning treatment options irrespective of their cultural background, the stage of disease and the patient's age. Increased information requirements regarding potential side effects and treatment alternatives were recorded. Besides the need for more effective therapy, alopecia and fatigue are the most important side effects of concern to patients.
Collapse
Affiliation(s)
- G Oskay-Özcelik
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
| | - S Alavi
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
| | - R Richter
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin
| | - M Keller
- North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
| | - R Chekerov
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany
| | - S C Cecere
- Division of Medical Oncolog, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
| | - G Cormio
- Department of Biomedical Science and Human Oncolog, Obstetrics and Gynecology Unit, University of Bari, Bari, Italy
| | - F Joly
- Department of Medical Oncolog, Centre Francois Baclesse, Universite Basse Normandie, Caen, France
| | - J E Kurtz
- Oncology and Hematology, Hôpitaux Universitaires de Strasbourg, Strasbourg
| | - A du Bois
- Deptartment of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte (KEM), Essen, Germany
| | - M Maciejewski
- Dolnoslaskie Centrum onkologii/Oddzial Ginekologii Onkologicznej, Wroclaw, Poland
| | - M Jedryka
- Department of Oncology and Gynaecological Oncology Clinic, Wroclaw Medical University, Wroclaw, Poland
| | - I Vergote
- Division of Gynaecological Oncol, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium
| | - E Van Nieuwenhuysen
- Division of Gynaecological Oncol, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium
| | - A Casado
- Department of Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - C Mendiola
- University Hospital 12 de Octubre, Madrid, Spain
| | - P Achimas-Cadariu
- Department of Surgery, The Oncology Institute Ion Chiricuţă, Cluj-Napoca, Romania; Department of Surgery and Gynecologic Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - C Vlad
- Department of Surgery, The Oncology Institute Ion Chiricuţă, Cluj-Napoca, Romania; Department of Surgery and Gynecologic Oncology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - D Reimer
- Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - A G Zeimet
- Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - M Friedlander
- Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
| | - J Sehouli
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Gynecology, Charité European Competence Center for Ovarian Cancer, Berlin; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany.
| |
Collapse
|
9
|
Welponer H, Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Marth C, Fiegl H, Zeimet AG. Die klinische Relevanz der miR-34 Familie beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1682000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- H Welponer
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - I Tsibulak
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - V Wieser
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - C Degasper
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - G Shivalingaiah
- Division für Humangenetik, Medizinische Universität Innsbruck
| | - S Wenzel
- Division für Humangenetik, Medizinische Universität Innsbruck
| | - S Sprung
- Institut für Pathologie, Medizinische Universität Innsbruck
| | - C Marth
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - AG Zeimet
- Universitätsklinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| |
Collapse
|
10
|
Leitner K, Wieser V, Tsibulak I, Degasper C, Welponer H, Reimer D, Wiedemair A, Marth C, Fiegl H, Zeimet AG. Die Expression von SMARCA4 beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1681992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- K Leitner
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - V Wieser
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - I Tsibulak
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - C Degasper
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - H Welponer
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - D Reimer
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - A Wiedemair
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - C Marth
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - AG Zeimet
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| |
Collapse
|
11
|
Knoll K, Berger A, Tsibulak I, Leitner K, Degasper C, Welploner H, Wieser V, Marth C, Fiegl H, Zeimet AG. Locusspezifische TP53-Mutationsanalyse. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1681990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- K Knoll
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - A Berger
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - I Tsibulak
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - K Leitner
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - C Degasper
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - H Welploner
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - V Wieser
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - C Marth
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| | - AG Zeimet
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Innsbruck
| |
Collapse
|
12
|
Wieser V, Tsibulak I, Degasper C, Welponer H, Leitner K, Sprung S, Haybäck J, Fiegl H, Marth C, Zeimet AG. RANKL als unabhängiger Prognoseparameter für Patientinnen mit Ovarialkarzinom. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1682001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- V Wieser
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - I Tsibulak
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - C Degasper
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - H Welponer
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - K Leitner
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - S Sprung
- Institute für Pathologie der Med. Universität Innsbruck
| | - J Haybäck
- Institute für Pathologie der Med. Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - C Marth
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - AG Zeimet
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| |
Collapse
|
13
|
Tsibulak I, Hackl H, Wieser V, Degasper C, Fiegl H, Marth C, Zeimet AG. BRCA2 mRNA-Expression als prognostisch relevanter Faktor beim Ovarialkarzinom: Validierung an der TCGA-Kohorte. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1681998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- I Tsibulak
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - H Hackl
- Sektion für Bioinformatik, Medizinische Universität Innsbruck
| | - V Wieser
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - C Degasper
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - H Fiegl
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - C Marth
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| | - AG Zeimet
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck
| |
Collapse
|
14
|
Degasper C, Brunner A, Sampson N, Tsibulak I, Wieser V, Welponer H, Marth C, Fiegl H, Zeimet AG. NADPH oxidase (NOX4) im normalen Endometrium und im Endometriumkarzinom. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1681987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- C Degasper
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - A Brunner
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - N Sampson
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - I Tsibulak
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - V Wieser
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - H Welponer
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - C Marth
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - H Fiegl
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| | - AG Zeimet
- Universitätsklinik für Frauenheilkunde und Geburtshilfe der Med. Universität Innsbruck
| |
Collapse
|
15
|
Berger A, Abdel Azim S, Tsibulak I, Shivalingaiah G, Wenzel S, Gaugg I, Fleischer M, Zeimet AG, Fiegl H, Zschocke J, Marth C. P53-Mutationsanalysen beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1599166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- A Berger
- Univ. Klinik für Gynäkologie und Geburtshilfe
| | | | - I Tsibulak
- Univ. Klinik für Gynäkologie und Geburtshilfe
| | - G Shivalingaiah
- Division für Humangenetik, Medizinische Universität Innsbruck, Innsbruck
| | - S Wenzel
- Division für Humangenetik, Medizinische Universität Innsbruck, Innsbruck
| | - I Gaugg
- Univ. Klinik für Gynäkologie und Geburtshilfe
| | - M Fleischer
- Univ. Klinik für Gynäkologie und Geburtshilfe
| | - AG Zeimet
- Univ. Klinik für Gynäkologie und Geburtshilfe
| | - H Fiegl
- Univ. Klinik für Gynäkologie und Geburtshilfe
| | - J Zschocke
- Division für Humangenetik, Medizinische Universität Innsbruck, Innsbruck
| | - C Marth
- Univ. Klinik für Gynäkologie und Geburtshilfe
| |
Collapse
|
16
|
Abdel Azim S, Tsibulak I, Berger A, Shivalingaiah G, Wenzel S, Gaugg I, Fleischer M, Zeimet AG, Marth C, Fiegl H. Klinische Relevanz der HRAS DNA-Methylierung beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1599161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- S Abdel Azim
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - I Tsibulak
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - A Berger
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - G Shivalingaiah
- Division für Humangenetik, Medizinische Universität Innsbruck, Innsbruck
| | - S Wenzel
- Division für Humangenetik, Medizinische Universität Innsbruck, Innsbruck
| | - I Gaugg
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - M Fleischer
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - AG Zeimet
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - C Marth
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - H Fiegl
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| |
Collapse
|
17
|
Tsibulak I, Berger A, Abdel Azim S, Shivalingaiah G, Wenzel S, Wiedemair A, Fiegl H, Marth C, Zeimet AG. BRCA2 mRNA-Expression als prognostisch relevanter Faktor beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1599181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- I Tsibulak
- Univ. Klinik für Gynäkologie und Geburtshilfe, Innsbruck
| | - A Berger
- Univ. Klinik für Gynäkologie und Geburtshilfe, Innsbruck
| | - S Abdel Azim
- Univ. Klinik für Gynäkologie und Geburtshilfe, Innsbruck
| | - G Shivalingaiah
- Division für Humangenetik, Medizinische Universität Innsbruck
| | - S Wenzel
- Division für Humangenetik, Medizinische Universität Innsbruck
| | - A Wiedemair
- Univ. Klinik für Gynäkologie und Geburtshilfe, Innsbruck
| | - H Fiegl
- Univ. Klinik für Gynäkologie und Geburtshilfe, Innsbruck
| | - C Marth
- Univ. Klinik für Gynäkologie und Geburtshilfe, Innsbruck
| | - AG Zeimet
- Univ. Klinik für Gynäkologie und Geburtshilfe, Innsbruck
| |
Collapse
|
18
|
Wieser V, Gaugg I, Fleischer M, Zeimet AG, Fiegl H, Marth C. Spermatogensis associated 2 (SPATA2) ist ein unabhängiger Prognosemarker für Patientinnen mit Ovarialkarzinom. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1599184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- V Wieser
- Medizinische Universität Innsbruck, Universitätsklinik für Gynäkologie und Gebursthilfe, Innsbruck
| | - I Gaugg
- Medizinische Universität Innsbruck, Universitätsklinik für Gynäkologie und Gebursthilfe, Innsbruck
| | - M Fleischer
- Medizinische Universität Innsbruck, Universitätsklinik für Gynäkologie und Gebursthilfe, Innsbruck
| | - AG Zeimet
- Medizinische Universität Innsbruck, Universitätsklinik für Gynäkologie und Gebursthilfe, Innsbruck
| | - H Fiegl
- Medizinische Universität Innsbruck, Universitätsklinik für Gynäkologie und Gebursthilfe, Innsbruck
| | - C Marth
- Medizinische Universität Innsbruck, Universitätsklinik für Gynäkologie und Gebursthilfe, Innsbruck
| |
Collapse
|
19
|
Wenzel SS, Shivalingaiah G, Fiegl H, Zeimet AG, Marth C, Wimmer K, Zschocke J. Kombinierte BRCA1/2-Mutations- und Kopienzahlanalyse in nativen Tumorproben des Ovarialkarzinoms. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1599183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
| | | | - H Fiegl
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - AG Zeimet
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | - C Marth
- Univ. Klinik für Gynäkologie und Geburtshilfe, Medizinische Universität Innsbruck, Innsbruck
| | | | | |
Collapse
|
20
|
Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rössler J, Marth C, Zeimet AG. Bewertung der Folat-Rezeptor 1 (FOLR1) mRNA-Expression, seine promotorspezifische DNA-Methylierung und die globale DNA-Hypomethylierung im Typ I und Typ II Ovarialkarzinom. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1579604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
21
|
Notaro S, Fiegl H, Reimer D, Duggan-Peer M, Wiedemair A, Rössler J, Altevogt P, Zeimet AG, Marth C. Evaluierung der L1CAM-Expression beim Endometriumkarzinom mittels quantitativer Real-time PCR. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1579602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
22
|
Notaro S, Reimer D, Fiegl H, Wiedermair A, Rössler J, Zeimet AG. Die Rolle der mir-34 Familie beim Typ I und Typ II Ovarialkarzinom. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1579601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
23
|
Notaro S, Duggan-Peer M, Fiegl H, Reimer D, Wiedemair A, Rössler J, Marth C, Zeimet AG. JARID1 Familie Transkript Evaluierung bei Ovarialkarzinom und deren Korrelationen mit BRCA-Gen-Mutation und Expression. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1579603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
24
|
Notaro S, Gaugg I, Fleischer M, Fiegl H, Zeimet AG, Marth C. Folatrezeptor-alpha (FOLR1) und seine Rolle beim Endometriumkarzinom. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1579605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
25
|
Holly J, Gindlhuber K, Reimer D, Marth C, Aigner F, Zeimet AG. Die Rolle des suspekten Lymphknotens im Herzzwerchfellwinkels beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1555076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
26
|
Abdel Azim S, Peer M, Reimer D, Fiegl H, Marth C, Zeimet AG. Einfluss der L1CAM Expression am Ovarialkarzinom auf die Krankheitsprogression und das Überleben. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1548601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
27
|
Wagener A, Zeimet AG, Reimer D, Hefler L, Koch H. Wertigkeit der Omentektomie bei serös papillärem und klarzelligem Endometriumkarzinom. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1548625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
28
|
Schmid G, Reimer D, Fiegl H, Marth C, Zeimet AG. Die Rolle der Expression von miR-34a und dessen Promotor-Methylationsstatus beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1548620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
29
|
Reitsamer R, Zeimet AG. Vorwort. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
30
|
Abdel Azim S, Reimer D, Maier H, Müller-Holzner E, Oberwalder M, Zeimet AG, Marth C. Ein seltener Uterustumor wird zum PECom der Darmwand - ein Fallbericht. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
31
|
Peer M, Fellner W, Seeber BE, Zeimet AG, Marth C. Primäres Endometriumkarzinom am Mons pubis - Ein Case Report. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
32
|
Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, Hatina J. Ovarian cancer stem cells. Neoplasma 2013; 59:747-55. [PMID: 22862176 DOI: 10.4149/neo_2012_094] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Because of its semi-solid character in dissemination and growth, advanced ovarian cancer with its hundreds of peritoneal tumor nodules and plaques appears to be an excellent in vivo model for studying the cancer stem cell hypothesis. The most important obstacle, however, is to adequately define and isolate these tumor-initiating cells endowed with the properties of anoikis-resistance and unlimited self-renewal. Until now, no universal single marker or marker constellation has been found to faithfully isolate (ovarian) cancer stem cells. As these multipotent cells are known to possess highly elaborated efflux systems for cytotoxic agents, these pump systems have been exploited to outline putative stem cells as a side-population (SP) via dye exclusion analysis. Furthermore, the cells in question have been isolated via flow cytometry on the basis of cell surface markers thought to be characteristic for stem cells.In the Vienna variant of the ovarian cancer cell line A2780 a proof-of-principle model with both a stable SP and a stable ALDH1A1+ cell population was established. Double staining clearly revealed that both cell fractions were not identical. Of note, A2780V cells were negative for expression of surface markers CD44 and CD117 (c-kit). When cultured on monolayers of healthy human mesothelial cells, green-fluorescence-protein (GFP)-transfected SP of A2780V exhibited spheroid-formation, whereas non-side-population (NSP) developed a spare monolayer growing over the healthy mesothelium. Furthermore, A2780V SP was found to be partially resistant to platinum. However, this resistance could not be explained by over-expression of the "excision repair cross-complementation group 1" (ERCC1) gene, which is essentially involved in the repair of platinated DNA damage. ERCC1 was, nonetheless, over-expressed in A2780V cells grown as spheres under stem cell-selective conditions as compared to adherent monolayers cultured under differentiating conditions. The same was true for the primary ovarian cancer cells B-57.In summary our investigations indicate that even in multi-passaged cancer cell lines hierarchic government of growth and differentiation is conserved and that the key cancer stem cell population may be composed of small overlapping cell fractions defined by various arbitrary markers.
Collapse
Affiliation(s)
- A G Zeimet
- Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Boesch M, Reimer D, Sopper S, Wolf D, Zeimet AG. Crossroads of Drug Resistance and Stem-Like Properties in Ovarian Cancer. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
34
|
Huemer D, Reimer D, Fessler S, Zeimet AG, Marth C. Peri- und postoperative Komplikationen der Debulking-Operation beim Ovarial-Carcinom an der Universitätsklinik für Frauenheilkunde Innsbruck von 2006-2011. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
35
|
Grimm C, Hofstetter G, Concin N, Marth C, Zeimet AG, Heinze G, Natter C, Rahhal-Schupp J, Reinthaller A, Polterauer S. Die Vorhersage des Gesamtüberlebens von Frauen mit Zervixkarzinom anhand eines Nomogramms. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
36
|
Jerabek-Klestil S, Widschwendter A, Abdel-Azim S, Müller-Holzner E, Fessler S, Georgoulopoulos A, Zelger B, Maier H, Fiegl M, Marth C, Zeimet AG. Immunhistochemische Charakterisierung neuroendokrin differenzierter kleinzelliger Zervixkarzinome. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
37
|
Hatina J, Reimer D, Sopper S, Boesch M, Martowicz A, Rössler J, Wiedemair A, Wolf D, Zeimet AG. Tumorstammzellen und die Biologie der Chemoresistenz beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
38
|
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Rahhal-Schupp J, Zeimet AG, Marth C, Reinthaller A, Concin N, Polterauer S. Der prognostische Wert von Gamma-Glutamyltransferase (GGT) in Patientinnen mit Ovarialkarzinom. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
39
|
Reitsamer R, Zeimet AG. EDITORIAL. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
40
|
Wasle IKC, Boesch M, Sopper S, Reimer D, Wolf D, Zeimet AG. Identification of Cancer Stem Cells in Primary Ovarian Carcinoma. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
41
|
Hubalek M, Bartsch R, Gnant M, Kapp KS, Lang A, Lax S, Lukas P, Neunteufel W, Pristauz G, Reitsamer R, Sandbichler P, Schrenk P, Singer C, Tamussino K, Tschmelitsch J, Zeimet AG, Marth C. Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. Geburtshilfe Frauenheilkd 2012; 72:293-298. [PMID: 25284834 DOI: 10.1055/s-0031-1298441] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
The prognosis of breast cancer is most heavily influenced by the status of the axillary nodes. Until a few years ago, this knowledge was gained through radical axillary lymph node clearance. In the meantime, sentinel lymph node clearance has become an established part of the surgical treatment of breast cancer. With the development of this procedure, the morbidity caused by axillary dissection has been reduced significantly. Although comprehensive prospective, randomised data regarding the safe use of the sentinel concept are only now available, the focus currently, however, is on the question of whether in the case of positive sentinel lymph nodes, an axillary dissection can be done away with altogether without having any negative impact on the risk of loco-regional recurrence or on progression-free survival and overall survival. The results of the American ACOSOG-Z001 study have changed the fundamental perspective of this. In this study on the advantages of axillary dissection following the confirmation of tumour tissue in the sentinel lymph nodes, there were no statistically significant advantages from axillary dissection for women with a favourable overall risk profile who had received radiotherapy and systemic therapy. If this concept takes hold, the surgical treatment of node-positive breast cancer, at least in the axilla, would be reduced to a minimum, and the focus of treatment would in future lie more on the systemic treatment of this condition. As part of an interdisciplinary consensus meeting, a standardised approach for Austria with regard to this question was decided upon.
Collapse
Affiliation(s)
- M Hubalek
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| | - R Bartsch
- University Department of Internal Medicine I, Breast Health Centre MUW/AKH, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | - M Gnant
- University Department of Surgery, Breast Health Centre MUW/AKH, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | - K S Kapp
- University Department of Radiotherapy/Radio-Oncology, Graz, Austria
| | - A Lang
- Feldkirch State Hospital, Dept. of Internal Medicine, Haematology and Medical Oncology, Feldkirch, Austria
| | - S Lax
- Graz West State Hospital, Institute of Pathology, Graz, Austria
| | - P Lukas
- University Department of Radiotherapy/Radio-Oncology, Innsbruck, Austria
| | - W Neunteufel
- Dornbirn Hospital, Department of Gynaecology and Obstetrics, Dornbirn, Austria
| | - G Pristauz
- University Department of Gynaecology and Obstetrics, Clinical Department of Gynaecology, Graz, Austria
| | - R Reitsamer
- St. Johanns-Spital/State Women's Hospital, University Department of Specialist Gynaecology, Salzburg, Austria
| | - P Sandbichler
- St.Vinzenz Hospital, Department of Surgery, Zams, Austria
| | - P Schrenk
- Linz City Hospital, Dept. of Surgery II, Breast Competence Centre, Linz, Austria
| | - C Singer
- Clinical Department of General Gynaecology and Gynaecological Oncology, Medical University of Vienna, Vienna, Austria
| | - K Tamussino
- University Department of Gynaecology and Obstetrics, Clinical Department of Gynaecology, Graz, Austria
| | - J Tschmelitsch
- Hospital of the Merciful Brothers, Surgical Department, St. Veit/Glan, Austria
| | - A G Zeimet
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| | - C Marth
- Department of Women's Health, Clin. Dept. of Gynaecology and Obstetrics, Innsbruck, Austria
| |
Collapse
|
42
|
Abdel-Azim S, Reimer D, Müller-Holzner E, Marth C, Zeimet AG. Immunhistochemischer Nachweis von L1-CAM im Stromasarkom und Carcinosarkom (MMMT) des Uterus. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
43
|
Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. Ann Oncol 2012; 23:1795-802. [PMID: 22228447 DOI: 10.1093/annonc/mdr568] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Overexpression of L1-cell adhesion molecule (L1CAM) has been observed for various carcinomas and correlates with poor prognosis and late-stage disease. In vitro, L1CAM enhances proliferation, cell migration, adhesion and chemoresistance. We tested L1CAM and interleukin-1 beta (IL-1β) expression in tumor samples and ascitic fluid from ovarian carcinoma patients to examine its role as a prognostic marker. PATIENTS AND METHODS We investigated tumor samples and ascitic fluid from 232 serous ovarian carcinoma patients for L1CAM by enzyme-linked immunosorbent assay. L1CAM expression was correlated with pathoclinical parameters and patients' outcome. IL-1β levels were measured in tumor cell lysates. Ovarian cancer cell lines were analyzed for the contribution of L1CAM to IL-1β production and nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB) activation. RESULTS We observed that L1CAM-expressing tumors show a highly invasive phenotype associated with restricted tumor resectability at primary debulking surgery and increased lymphogenic spread. Soluble L1CAM proved to be a marker for poor progression-free survival and chemoresistance. In ovarian carcinoma cell lines, the specific knock-down of L1CAM reduces IL-1β expression and NF-κB activity. CONCLUSIONS L1CAM expression contributes to the invasive and metastatic phenotype of serous ovarian carcinoma. L1CAM expression and shedding in the tumor microenvironment could contribute to enhanced invasion and tumor progression through increased IL-1β production and NF-κB activation.
Collapse
Affiliation(s)
- S Bondong
- Department of Translational Immunology, German Cancer Research Center, Heidelberg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Reimer D, Kiefel H, Hubalek M, Erdel M, Concin N, Hofstetter G, Mueller-Holzner E, Altevogt P, Marth C, Zeimet AG. Epidermal growth factor-mediated signaling in ovarian cancer and the role of miR-34a and 6p22 gene amplification-based E2F3a control. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Zeimet AG, Abdel-Azim S, Reimer D, Mueller-Holzner E, Winterhoff B, Puistola U, Ben-Arie A, vanKempen L, Amant F, Petru E, Jahn S, Polterauer S, Oppelt P, Weigert M, Altevogt P, Huszar M, Marth C, Fogel M. Large international multicenter evaluation of the clinical significance of L1-CAM expression in FIGO stage I, type 1 endometrial cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5091] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Reimer D, Kiefel H, Erdel M, Müller-Holzner E, Fiegl H, Marth C, Altevogt P, Zeimet AG. 6p22-Genamplifikation und Methylierung des miR-34a Promoters, zwei EGF-R unabhängige Mechanismen der E2F3a-Regulation beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1280643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
47
|
Hofstetter G, Berger A, Schuster E, Wolf A, Holzer B, Fiegl H, Marth C, Zeimet AG, Tong D, Zeillinger R, Concin N. Die N-terminal verkürzten p53-Isoformen Δ40p53 und Δ133p53 beeinflussen die Prognose bei Patientinnen mit fortgeschrittenen serösen Ovarialkarzinomen - eine prospektive Multizenterstudie. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1280632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
48
|
Hofstetter G, Berger A, Schuster E, Chamson M, Müller-Holzner E, Marth C, Zeimet AG, Zeillinger R, Concin N. Die klinische Bedeutung des MDM2 SNP 309 beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1280631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
49
|
Wolf DG, Fong D, Scherrer L, Wolf A, Reimer D, Marth C, Mueller-Holzner E, Braun S, Zeimet AG. Treg and T eff in the bone marrow of early-stage breast cancer patients with disseminated tumor cells. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e21049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Braicu EI, Zeillinger R, Vergote IB, Mahner S, Zeimet AG, Cadron I, Castillo-Tong D, Chekerov R, Brandt B, Sehouli J. Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|